Download Caris Life Sciences Announces Presentations at AACR 2017 Annual

FOR IMMEDIATE RELEASE
Caris Life Sciences Announces Presentations at AACR 2017 Annual Meeting
Demonstrating the Broad Capabilities of ADAPT Biotargeting System™
Caris’ Novel Profiling Platform Facilitates a Deeper Understanding of Molecular Complexes to
Support Drug Development and Advance Precision Medicine
IRVING, Texas, Mar. 21, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on
fulfilling the promise of precision medicine, today announced four abstracts that will be presented at
the American Association for Cancer Research (AACR) 2017 Annual Meeting on April 1-5 in Washington,
D.C. The broad capabilities of the company’s ADAPT Biotargeting System™ include therapeutic discovery
and development, fixed tissue based companion diagnostics, blood-based cancer screening and
biomarker identification (proteins and nucleic acids).
“The ADAPT Biotargeting System is a powerful, novel platform to profile biological samples on a
systems-wide scale through the use of highly diverse libraries of single-stranded oligodeoxynucleotide
(ssODNs) aptamers that bind to individual and multi-component targets,” said David Spetzler, Ph.D.,
M.B.A., President and Chief Scientific Officer of Caris Life Sciences. “These abstracts show very clearly
that the ADAPT Biotargeting System can address a broad range of important needs, including biomarker
discovery (abst. 2214), diagnostics (abst. 2754) and drug lead discovery (abst. 2469). Along with Caris’
other leading edge capabilities, such as deep sequencing of circulating nucleic acids (abst. 4437), the
ADAPT Biotargeting System enables us to examine and understand complex biological networks
underlying healthy and diseased states. We believe this platform can dramatically accelerate precision
medicine.”
AACR Abstract Summaries
Abstract 2214 / Poster 13: Adaptive Dynamic Artificial Polyligand Targeting (ADAPT): A Method to
Identify Exosomal Proteins from a Prostate Cancer Cell Line
Summary: ADAPT was used to identify cancer-associated proteins expressed on exosomes. The platform
can be used across multiple cancer types for biomarker discovery.
Date:
April 3, 2017
Time:
1:00 – 5:00 p.m. EDT
Location:
Section 9
Abstract 2469 / Poster 26: The B-cell Lymphoma Specific Aptamer 10.36 Binds a Ribonucleoprotein
Complex on the Cell Surface of Cancer Cells
Summary: A specific DNA aptamer was identified as a potential targeted therapy to treat Myc expressing
malignancies.
Date:
April 3, 2017
Time:
1:00 – 5:00 p.m. EDT
Location:
Section 18
Abstract 2754 / Poster 24: A novel liquid biopsy method for development of aptamer libraries that
bind blood plasma exosomes from breast cancer patients
Summary: ADAPT™ was used to identify binding signatures in plasma exosomes that distinguish breast
cancer patients from healthy controls.
Date:
April 3, 2017
Time:
1:00 – 5:00 p.m. EDT
Location:
Section 30
Abstract 4437 / Poster 15: Small non-coding RNA profiling from prostate cancer plasma by deep
sequencing
Summary: High-depth expression profiling of circulating small RNAs revealed signatures associated with
prostate cancer.
Date:
April 4, 2017
Time:
1:00 – 5:00 p.m. EDT
Location:
Section 18
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of
precision medicine through quality and innovation. The company’s ADAPT Biotargeting System™ is a
revolutionary and unbiased profiling platform with applications across therapy development, drug
delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other
complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of
molecular interactions within complex biological systems in their natural state(s). Caris also offers
comprehensive tumor profiling services through its patented and proprietary product, Caris Molecular
Intelligence® (CMI). With more than 110,000 clinical cases, CMI provides oncologists with the most
clinically actionable treatment options available to personalize cancer care today. Headquartered in
Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international
markets. To learn more, please visit www.CarisLifeSciences.com.
###
Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
[email protected] / [email protected]
Tel: +1-508-280-6592 / +1-646-536-7006
Source: Caris Life Sciences
Caris Life Sciences Media Relations & Corporate Affairs
[email protected]
214-294-5606